AZN Oct 2024 65.000 put
| Previous Close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.0600 |
| Ask | 0.1400 |
| Strike | 65.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.1500 - 0.1500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 769 |
Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
WILMINGTON, Del., September 13, 2024--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial clinical activity in a large cohort of patients with HER2-positive metastatic breast cancer who have brain metastases and received no more than two prior lines of therapy in the metastatic setting. Results will be presented today as a late-breaking presentation (abstract #LBA18) at the European Society
BloombergAstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls
(Bloomberg) -- AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the British drugmaker’s experimental lung cancer medicine with partner Daiichi Sankyo Co. prompted two analyst downgrades. Most Read from BloombergHousing’s Worst Crisis in Decades Reverberates Through 2024 RaceFrom Louisville, a Push to Plant Trees for Public HealthAn Affordable Nomadic Home Design Struggles to Adapt to Urban LifeFor Tenants, AI-Powered Screening
ZacksIonis Stock Drops 12% on Pricing of $500M Common Stock Offering
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
